The Gore Viabahn VBX balloon expandable endoprosthesis has received US Food & Drug Administration (FDA) approval for treatment of de novo or restenotic lesions found in iliac arteries, including lesions at the aortic bifurcation. This marks the availability of the only balloon expandable stent graft with an indication for the iliac artery.
The use of hypnosis during endovascular aneurysm repair (EVAR) may improve haemodynamic and respiratory stability and allow faster patient recovery, according to a presentation given at the 2016 VEITHsymposium (15–19 November, New York, USA).
While the long-term durability of fenestrated endovascular repair (FEVAR) has been established, the need for accurate procedural planning may act as a barrier to widespread adoption. At the 2016 VEITHsymposium (15-19 November, New York, USA), Benjamin Starnes, University of Washington, Seattle, USA, suggested that this barrier may be overcome thanks to AortaFit automated planning software.
Remote monitoring of bypass flow using an implantable piezoelectric sensor, which can also be placed on stents, has shown successful and reliable transmission of signal over the first 30 days of an in vivo study. The experiment, which used the Graftworx system in an ovine carotid artery bypass model, raises the possibility of remote monitoring of vascular flow using wireless technology.
Despite homogenous professional society recommendations, significant global variation still exists in the management of abdominal aortic aneurysms, a US study published in Circulation has shown. The variation is especially marked in intact aneurysm diameter at repair, use of endovascular aneurysm repair (EVAR) and the treatment of elderly patients, the authors, led by Adam W Beck (Birmingham, USA) and Kevin Mani (Uppsala, Sweden), report.
QT Vascular has signed a definitive agreement with Medtronic, for the worldwide distribution of its Chocolate percutaneous transluminal angioplasty (PTA) catheter for a period of five years and automatically renewable for two additional one-year periods. The parties continue to negotiate other aspects of their commercial relationship.
As the second year of enrolment draws to a close, the Best Endovascular vs. Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial is well on its way to attaining its target enrolment. In the process, it is serving as a catalyst for an ongoing discussion of how CLI, which affects 8–10 million people worldwide, is optimally managed. This multidisciplinary trial, led by Alik Farber (Boston Medical Center, Boston, USA), Matthew Menard (Brigham and Women’s Hospital, Boston, USA) and Kenneth Rosenfield (Massachusetts General Hospital, Boston, USA), is currently enrolling patients at 135 sites in the USA and Canada. BEST-CLI both encourages and facilitates specialists who treat CLI at a given trial site to work together for the common good of patients, and in so doing, harnesses the talents of all contributing specialties. Key to successful engagement in the effort is the ability of participating investigators to set aside their individual treatment biases and acknowledge the absence of reliable scientific evidence to support their impulses.
Mahmood Razavi and George Adams, the national co-principal unvestigators of Mercator MedSystem’s DANCE trial, have each presented comprehensive 13-month data from the trial during late-breaking sessions at International Symposium on Endovascular Therapy (ISET; 4-8 February, Holywood, USA) and Leipzig Interventional Course (LINC; 24-27 January, Leipzig, Germany), respectively.
Flow Forward Medical has announced the completion of a preclinical study and a computational fluid dynamics study supporting continued development of the company’s Arteriovenous Fistula Eligibility (AFE) system. The AFE system is a small external blood pump designed for temporary use to stimulate flow-mediated vein dilation to make more haemodialysis patients eligible for creation of arteriovenous fistula (AVF) and arteriovenous graft (AVG) vascular access sites, and to increase success rates after AVF and AVG surgeries.
Intact Vascular’s TOBA II BTK (Tack optimised balloon angioplasty II below the knee) clinical trial has commenced enrolment, with the first patient treated by Joseph Cardenas at Yuma Regional Hospital and the Heart, Lung and Vascular Center in Yuma, USA.
Micro Medical Solutions (MMS) has received CE mark approval for MicroStent, allowing the company to market this technology in Europe. MicroStent is a vascular stent specifically designed to reduce below-the-knee amputations for critical limb ischaemia (CLI) resulting from peripheral artery disease. It is the third MMS product to receive CE mark approval in the past year.
Endologix has completed patient enrolment in the Lucy (Evaluation of females who are underrepresented candidates for abdominal aortic aneurysm repair) study, a multicentre post-market registry designed to explore the clinical benefits associated with endovascular aneurysm repair (EVAR) using the Ovation abdominal stent graft platform in female patients with abdominal aortic aneurysms (AAA), as compared to males. It is the first prospective study evaluating EVAR in females, a population that has historically been underrepresented in EVAR clinical trials.
Heavy alcohol drinking habits over the years may prematurely age arteries, especially in men, putting them at an increased risk for heart disease, according to new research in Journal of the American Heart Association, the open access journal of the American Heart Association/American Stroke Association.
Benjamin W Starnes, chief of Vascular Surgery at the University of Washington, USA, and one of the world’s foremost authorities on the treatment of abdominal aortic aneurysms, has announced midterm results from his physician-sponsored investigational device exemption (IDE) study, administered in conjunction with Harborview Medical Center, Seattle, USA. The ongoing study evaluates physician-modified endovascular grafts (PMEG) for the treatment of juxtarenal aortic aneurysms and assesses a new technology developed by Aortica that could significantly reduce the need for invasive open surgery in patients with aneurysms originating too close to branch arteries that supply blood to vital organs. Results from the first 60 patients using manual planning were recently published in the February issue of the Journal of Vascular Surgery (JVS).
Cagent Vascular has announced US Food and Drug Administration 510(k) clearance of its lead product, the Serranator Alto percutaneous transluminal angioplasty serration balloon catheter. The Serranator is the first of a family of peripheral artery disease technologies under development which incorporate proprietary Serration technology to an angioplasty balloon.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos